申请人:Neurogen Corporation
公开号:US05326868A1
公开(公告)日:1994-07-05
The present invention encompasses structures of the formula: ##STR1## and the pharmaceutically acceptable non-toxic salts thereof wherein: ##STR2## and X represents hydrogen, halogen, or hydroxy; W represents an aryl group unsubstituted or substituted with various organic and inorganic substituents; A, B, C, D, and E represent carbon or nitrogen substituted with hydrogen or various organic and inorganic substituents; and R.sub.3, and R.sub.4 are variables representing various organic and inorganic substituents.. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine drugs, and enhancement of memory.
本发明涵盖了以下结构的化合物:##STR1##及其药学上可接受的无毒盐,其中:##STR2##和X代表氢、卤素或羟基;W代表未取代或取代有各种有机和无机取代基的芳基;A、B、C、D和E代表碳或氮,取代有氢或各种有机和无机取代基;R.sub.3和R.sub.4是代表各种有机和无机取代基的变量。这些化合物是GABAa脑受体的高度选择性激动剂、拮抗剂或逆拮抗剂,或其前药,可用于焦虑、睡眠和癫痫障碍的诊断和治疗、苯二氮卓类药物过量和记忆增强。